Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Página do item simplificado
dc.contributor.authorSabongi, Juliano Guerra
dc.contributor.authorPereira Goncalves, Monica Carboni
dc.contributor.authorCasado Alves, Cira Danielle
dc.contributor.authorAlves, Joao
dc.contributor.authorScapulatempo-Neto, Cristovam
dc.contributor.authorMoriguchi, Sonia Marta [UNESP]
dc.contributor.institutionMed Ctr Sorocaba
dc.contributor.institutionBarretos Canc Hosp
dc.contributor.institutionDr Ary Pinheiro Base Hosp
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T17:12:12Z
dc.date.available2018-11-26T17:12:12Z
dc.date.issued2016-11-01
dc.description.abstractEsthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high. Treatment of neuroendocrine tumors using radionuclides bound to somatostatin analogues is well established in clinical practice. However, a standard and effective therapeutic approach has not been reported for ENB. The current study described the case of a 74-year-old female with numerous recurrences of ENB following multiple treatments and without possibility of resection. The patient was treated with the radiolabeled-somatostatin analogue, (177)Lutetium-DOTA-octreotate (Lu-177-DOTA-TATE), which successfully controlled the disease. This suggests that Lu-177-DOTA-TATE is a potential treatment for ENB and may represent an effective alternative and novel therapeutic strategy for this disease.en
dc.description.affiliationMed Ctr Sorocaba, Imaging Med Ctr, Div Nucl Med, BR-18031480 Sorocaba, SP, Brazil
dc.description.affiliationBarretos Canc Hosp, Dept Nucl Med, BR-14780000 Barretos, SP, Brazil
dc.description.affiliationBarretos Canc Hosp, Dept Head & Neck Surg, BR-14780000 Barretos, SP, Brazil
dc.description.affiliationDr Ary Pinheiro Base Hosp, Dept Nucl Med, BR-76804373 Porto Velho, RO, Brazil
dc.description.affiliationBarretos Canc Hosp, Dept Pathol Anat, BR-18600000 Barretos, SP, Brazil
dc.description.affiliationSao Paulo State Univ, Dept Trop Dis & Diagnost Imaging, Botucatu Med Sch, Dist Rubiao Jr S-N, BR-18618970 Botucatu, SP, Brazil
dc.description.affiliationUnespSao Paulo State Univ, Dept Trop Dis & Diagnost Imaging, Botucatu Med Sch, Dist Rubiao Jr S-N, BR-18618970 Botucatu, SP, Brazil
dc.format.extent3078-3082
dc.identifierhttp://dx.doi.org/10.3892/etm.2016.3732
dc.identifier.citationExperimental And Therapeutic Medicine. Athens: Spandidos Publ Ltd, v. 12, n. 5, p. 3078-3082, 2016.
dc.identifier.doi10.3892/etm.2016.3732
dc.identifier.issn1792-0981
dc.identifier.urihttp://hdl.handle.net/11449/162195
dc.identifier.wosWOS:000388822000044
dc.language.isoeng
dc.publisherSpandidos Publ Ltd
dc.relation.ispartofExperimental And Therapeutic Medicine
dc.relation.ispartofsjr0,510
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectesthesioneuroblastoma
dc.subjectlutetium 177
dc.subjectneuroendocrine tumors
dc.subjectolfactory neuroblastoma
dc.subjectnuclear medicine
dc.subjectradioisotopes
dc.titleLutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case reporten
dc.typeArtigo
dcterms.rightsHolderSpandidos Publ Ltd
unesp.author.orcid0000-0002-8920-6579[5]

Arquivos

Coleções

Artigos - Doenças Tropicais e Diagnósticos por Imagem - FMB